Fundz

Lucid Diagnostics closes $15 million financing through Series C Preferred Stock private placement, bolstering its balance sheet. The funding supports near-term commercial acceleration following the start of Medicare reimbursement for EsoGuard.

PUBLIC · LUCDOct 22, 2026

Amount Raised

$15 Million

Round Type

Series C

New YorkBiotechnology

Description

Lucid Diagnostics Inc. has begun receiving payments from Medicare for its EsoGuard® Esophageal DNA Test. The company closed a $15.0 million private placement for shares of its newly designated Series C Convertible Preferred Stock to existing long-term shareholders. This financing aims to strengthen Lucid's balance sheet and extend its cash runway

Quick answer

Lucid Diagnostics raised $15 Million in a Series C round, dated October 21, 2026. Lucid Diagnostics is based in New York, New York, United States.

How much did Lucid Diagnostics raise?
Lucid Diagnostics raised $15 Million in a Series C round on October 21, 2026.
What does Lucid Diagnostics do?
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
Where is Lucid Diagnostics based and how big is it?
Lucid Diagnostics is based in New York, New York, United States. Fundz records about 106 employees.
Who are the decision-makers at Lucid Diagnostics?
Fundz holds 5 contacts at Lucid Diagnostics, including the Senior Vice President of Sales. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Lucid Diagnostics that raised within 45 days of this round, from Fundz verified event records.

  • VETmAb Biosciences raised an undisclosed amount on November 17, 2026.
  • NRGene Canada raised $250K on November 17, 2026.
  • Soombit AI raised $9M (Series A) on November 17, 2026.
  • Qluster raised $5.2M (Pre-Seed) on November 17, 2026.
  • AstraNu raised $3.5M (Seed) on November 17, 2026.
  • Science Corporation raised $400M (Series D) on November 17, 2026.

Who to call at Lucid Diagnostics, and when

A new round usually means Lucid Diagnostics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Lucid Diagnostics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Lucid Diagnostics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Lucid Diagnostics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Lucid Diagnostics

Location

360 MADISON AVENUE

New York, New York, United States

About

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Lucid Diagnostics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

5 contacts
Verified contactsJohn, Senior Vice President of Sales hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Lucid Diagnostics's next move

See what Strategic adds

Lucid Diagnostics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.